3-iodobenzylguanidine has been researched along with End Stage Liver Disease in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fukuhara, E; Fukunami, M; Furukawa, Y; Hakui, H; Ikeda, I; Ishimi, M; Iwasaki, Y; Kawasaki, M; Kikuchi, A; Kondo, T; Morita, T; Ozaki, T; Sakata, Y; Sato, Y; Seo, M; Tamaki, S; Yamada, T | 1 |
1 other study(ies) available for 3-iodobenzylguanidine and End Stage Liver Disease
Article | Year |
---|---|
Usefulness of Cardiac MetaIodobenzylguanidine Imaging to Improve Prognostic Power of the Model for End-Stage Liver Disease Scoring System in Patients With Mild-to-Moderate Chronic Heart Failure.
Topics: 3-Iodobenzylguanidine; End Stage Liver Disease; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Severity of Illness Index; Time Factors; Ventricular Function, Left | 2016 |